Asia-Pacific biotech entering the US
0%
less time to pre-IND submission
The IND pathway identified, the preclinical gap analysis run, and submission-ready documents produced in weeks. Pre-IND meeting secured ahead of schedule.
We takelife-sciencecompanies intothe United States.
We specialize in therapeutics and medical devices from Japan, China, Korea and Europe. We focus on entity and capital formation, licensing and partnerships, commercial launch.
Our recent clients.
Juntendo University
Cross-border business development and strategy for a next-generation cell-therapy venture.
Energenesis Biomedical
International business development and licensing.
DLeader
Toxicology-assessment business and cross-border development.
Devis
Commercialization risk assessment, market research and PMDA regulatory strategy in women's health.
The first thing we ask: what is your long-term plan?
We will find a partner, lead meetings, negotiate the term sheet.
- 1
Find the licensee
We shortlist the buyers whose pipelines have the gap your asset can fill, and we know their search-and-evaluation teams by name.
- 2
Meet them
Introductory meetings, then the second and third ones, with us being part of negotiations.
- 3
Negotiate the term sheet
Upfront, milestones, royalties. We will work alongside a specialist US life-science law firm.
- 1
We will find a partner, lead meetings, negotiate the term sheet.
- 1
Find the licensee
We shortlist the buyers whose pipelines have the gap your asset can fill, and we know their search-and-evaluation teams by name.
- 2
Meet them
Introductory meetings, then the second and third ones, with us being part of negotiations.
- 3
Negotiate the term sheet
Upfront, milestones, royalties. We will work alongside a specialist US life-science law firm.
Our recent success.
European medical device, US entry
0 months
to commercial launch
Entity formation, 510(k) strategy, reimbursement mapping and distribution agreements built in parallel. First purchase orders in month five.
Engagements on retainer.
We offer you predictability and do not bill by the hour. Our fees are always flat and tied to milestones. Where there is a deal to close, a success fee on top.
- Retainer plus success feeAlways
- Success fee aloneNever
- Free asset searchesNever
- Price before the planNever
Most clients pay in a currency weaker than the dollar. We understand that knowing the cost upfront matters.
We are a boutique firm with a tailored approach.
Ten years in international diplomacy brokering life-science partnerships across borders, then Arcstone. A medical degree and a master’s in health economics behind the regulatory judgement, and a network built one deal at a time behind the introductions.
The pattern that started the firm: companies from Japan, Korea and Taiwan that tried the United States failed more often than they succeeded, usually because a home-country executive was sent to do an American job. Entering this market takes an American entity, American capital and an American commercial plan.
Julien takes the first conversation and stays accountable to the last. Regulatory consultants and subject-matter experts join where the work needs them. The research and drafting run on our own tooling, which is why a firm this size moves at this speed.
2018
Founded
MD MPH
Physician, health economist
20+
Licensing deals closed
JP · KR · China · EU
Where the work originates